# Biogen

Source: https://onco.cc/companies/biogen/  
OnCo record `biogen` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Biogen is the Massachusetts biotech that, as Biogen Idec, co-developed rituximab, the first antibody approved for cancer; it now concentrates on neurology.

## Summary

Biogen, founded in 1978 and headquartered in Cambridge, Massachusetts, merged with IDEC Pharmaceuticals in 2003 to form Biogen Idec. IDEC had developed rituximab (Rituxan) with Genentech, the anti-CD20 antibody approved in 1997 for follicular lymphoma, and Biogen Idec led lymphoma trials for it and for the radiolabelled antibody ibritumomab tiuxetan (Zevalin). The company later returned to the Biogen name and focuses on neurological and rare diseases; its phase 3 cancer trials on ClinicalTrials.gov date from the lymphoma era.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Biogen Inc.; Biogen Idec; IDEC Pharmaceuticals
- Tags: ctgov-sponsor
- HQ: Cambridge, MA
- Type: biotech
- Website: https://www.biogen.com

## Sources

- Official website: https://www.biogen.com
- ClinicalTrials.gov: trials led by Biogen: https://clinicaltrials.gov/search?lead=Biogen
- Wikidata: https://www.wikidata.org/wiki/Q864338

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- drugs: [Rituximab](https://onco.cc/drugs/rituximab/)

---
JSON: https://onco.cc/api/v1/entities/biogen.json